Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · IEX Real-Time Price · USD
13.70
+0.06 (0.44%)
Aug 11, 2022 4:00 PM EDT - Market closed
0.44%
Market Cap 382.61M
Revenue (ttm) 1.73M
Net Income (ttm) -86.65M
Shares Out 27.93M
EPS (ttm) -5.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 453,634
Open 13.70
Previous Close 13.64
Day's Range 13.45 - 14.33
52-Week Range 9.47 - 22.00
Beta 1.18
Analysts Buy
Price Target 33.77 (+146.5%)
Earnings Date Aug 15, 2022

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viri... [Read more...]

Industry Biotechnology
Founded 2006
CEO William Marshall
Employees 50
Stock Exchange NASDAQ
Ticker Symbol VRDN
Full Company Profile

Financial Performance

In 2021, VRDN's revenue was $2.96 million, an increase of 182.19% compared to the previous year's $1.05 million. Losses were -$79.41 million, -28.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is 33.77, which is an increase of 146.50% from the latest price.

Price Target
$33.77
(146.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from s...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact ...

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridi...

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...

Viridian Therapeutics to Participate in June Investor Conferences

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022 -- ...

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by ...

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF...

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care -

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- -- VR...

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call...

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...

Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease

The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Developmen...

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection - - Company expects to report top line VRDN-002 Phase 1 clinical...

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration -                   - Company ...

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (...

- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED - - Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 -

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R A...

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from s...

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -5.04% and -79.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

WALTHAM, Mass, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from se...

Viridian Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserve...

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment...

- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 -

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American...

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...